-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
7 views
Novo Nordisk's price has regained momentum in recent weeks after seeing a big slump earlier in 2025. With strong financials, and robust profit estimates even after a downgrade in outlook, NVO could continue to rise. There are risks to the stock as well, though, from losing market share to compounder versions of its blockbuster GLP-1 drugs.
